Société Générale — M&A Activity 2021

Feb 2, 2021

National Storage Mechanism | Additional information

RNS Number : 6816N

Societe Generale SA

02 February 2021

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1.       KEY INFORMATION

Name of person dealing (Note 1)	Société Générale S.A.
Company dealt in	Willis Towers Watson plc
Class of relevant security to which the dealings being disclosed relate (Note 2)	US$0.000304635 ordinary shares
Date of dealing	01/02/2021

2.         INTERESTS AND SHORT POSITIONS

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
Number	(%)	Number	(%)
(1) Relevant securities	907,137	0.70	20,207	0.02
(2) Derivatives (other than options)	1,408	0.00	8,131	0.01
(3) Options and agreements to purchase/sell	0	0.00	0	0.00
Total	*2,198,224	*1.71	28,338	0.02

* Include the holding of 1,289,679 shares on borrow products

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

Ap20

1.       DEALINGS (Note 4)

(a)      Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit USD (Note 5)
Purchase	77	207.45
Purchase	100	209.53
Purchase	2	207.08
Purchase	98	207.08
Purchase	100	207.86
Purchase	638	207.45
Purchase	1,672	207.45
Purchase	232	207.45
Sale	8	204.538
Sale	24	206.45
Sale	24	206.23
Sale	16	205.85
Sale	24	205.7
Sale	97	205.94
Sale	3	205.94
Sale	100	208.3
Sale	24	206.4
Sale	34	206.23
Sale	10	207.11
Sale	11	209.51
Sale	15	207.3
Sale	4	206.35
Sale	30	206.36
Sale	100	206.33
Sale	95	206.3
Sale	30	206.15
Sale	100	206
Sale	30	208.45
Sale	100	208.43
Sale	1	203.94
Sale	100	206.32
Sale	90	203.94
Sale	15	203.94
Sale	19	204.04
Sale	18	204.62
Sale	11	205.29
Sale	2	205.3
Sale	50	205.77
Sale	28	205.3
Sale	3	205.72
Sale	28	204.38
Sale	32	205.07
Sale	100	207.65
Sale	8	205.72
Sale	52	205.07
Sale	4,432	207.45
Sale	1	207.51
Sale	100	207.11
Sale	380	207.45
Sale	380	207.45
Total Purchases	2,919
Total Sales	6,729

(b)      Derivatives transactions (other than options transactions)

Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit USD (Note 5)

(c)      Options transactions in respect of existing relevant securities

(i)       Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)

(ii)      Exercising

Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

Ap21

2.       OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any

relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Is a Supplemental Form 8 attached? (Note 9)                                            No

Date of disclosure	02/02/2021
Contact name	Société Générale - Disclosure team
Telephone number	+33 1 42 14 92 74
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ISEFIFIRFDIFIIL